↓ Skip to main content

Advances in Dementia Research

Overview of attention for book
Cover of 'Advances in Dementia Research'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 White matter changes: the clinical consequences in the aging population
  3. Altmetric Badge
    Chapter 2 Longitudinal change of white matter abnormalities
  4. Altmetric Badge
    Chapter 3 Genetic aspects of microangiopathy-related cerebral damage
  5. Altmetric Badge
    Chapter 4 Research criteria for subcortical vascular dementia in clinical trials
  6. Altmetric Badge
    Chapter 5 How can cerebral infarcts and hemorrhages lead to dementia?
  7. Altmetric Badge
    Chapter 6 Vascular aspects in Alzheimer’s disease
  8. Altmetric Badge
    Chapter 7 Novel imaging technologies in the assessment of cerebral ageing and vascular dementia
  9. Altmetric Badge
    Chapter 8 Alzheimer disease and neuroinflammation
  10. Altmetric Badge
    Chapter 9 The immunological microenvironment in the CNS: implications on neuronal cell death and survival
  11. Altmetric Badge
    Chapter 10 Toxic effector molecules in the pathogenesis of immune-mediated disorders of the central nervous system
  12. Altmetric Badge
    Chapter 11 Cytokines in CNS disorders: neurotoxicity versus neuroprotection
  13. Altmetric Badge
    Chapter 12 Do neuronal inclusions kill the cell?
  14. Altmetric Badge
    Chapter 13 Mechanisms of cell death in neurodegenerative disorders
  15. Altmetric Badge
    Chapter 14 Estrogens, apoptosis and cells of neural origin
  16. Altmetric Badge
    Chapter 15 Markers of apoptosis and models of programmed cell death in Alzheimer’s disease
  17. Altmetric Badge
    Chapter 16 Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease
  18. Altmetric Badge
    Chapter 17 Genetics of Alzheimer’s disease — routes to the pathophysiology
  19. Altmetric Badge
    Chapter 18 Secretion of the amyloid precursor protein is elevated isoform specifically by apolipoprotein E4
  20. Altmetric Badge
    Chapter 19 Alterations in neurotrophins and neurotrophin receptors in Alzheimer’s disease
  21. Altmetric Badge
    Chapter 20 Genetically altered transgenic models of Alzheimer’s disease
  22. Altmetric Badge
    Chapter 21 Morphological substrates of mental dysfunction in Lewy body disease: an update
  23. Altmetric Badge
    Chapter 22 Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach
  24. Altmetric Badge
    Chapter 23 Understanding the role of estrogen on cognition and dementia
  25. Altmetric Badge
    Chapter 24 Present and future of Alzheimer therapy
  26. Altmetric Badge
    Chapter 25 Trials to slow progression and prevent disease onset
  27. Altmetric Badge
    Chapter 26 Epidemiologic clues to the causes and routes to prevention of Alzheimer disease
  28. Altmetric Badge
    Chapter 27 Post-transcription modulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived factors
  29. Altmetric Badge
    Chapter 28 A brain derived peptide preparation reduces the translation dependent loss of a cytoskeletal protein in primary cultured chicken neurons
  30. Altmetric Badge
    Chapter 29 Neurotrophic effects of Cerebrolysin ® in animal models of excitotoxicity
  31. Altmetric Badge
    Chapter 30 Cerebrolysin ® reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection
  32. Altmetric Badge
    Chapter 31 Clinical experience with Cerebrolysin®
  33. Altmetric Badge
    Chapter 32 Approach towards an integrative drug treatment of Alzheimer’s disease
  34. Altmetric Badge
    Chapter 33 Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects.
Attention for Chapter 33: Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects.
Altmetric Badge

Mentioned by

video
1 YouTube creator

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
21 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects.
Chapter number 33
Book title
Advances in Dementia Research
Published in
Journal of neural transmission Supplementum, January 2000
DOI 10.1007/978-3-7091-6781-6_33
Pubmed ID
Book ISBNs
978-3-21-183512-8, 978-3-70-916781-6
Authors

Alvarez, X A, Lombardi, V R, Corzo, L, Pérez, P, Pichel, V, Laredo, M, Hernández, A, Freixeiro, F, Sampedro, C, Lorenzo, R, Alcaraz, M, Windisch, M, Cacabelos, R, Álvarez, X. Antón, Lombardi, V. R. M., Corzo, L., Pérez, P., Pichel, V., Laredo, M., Hernández, A., Freixeiro, F., Sampedro, C., Lorenzo, R., Alcaraz, M., Windisch, M., Cacabelos, R.

Abstract

Cerebrolysin is a porcine brain derived peptide preparation with potential neurotrophic activity. The effects of a single oral dose of the Cerebrolysin solution (30 ml) on brain bioelectrical activity and on cognitive performance were investigated in healthy elderly people. A single oral dose of Cerebrolysin induced a progressive increase in relative alpha activity power from 1 to 6 hours after treatment in almost all the brain electrodes in elderly control subjects. As compared with baseline alpha power (45.8+/-9.5%), the increase in relative alpha activity in the left occipital electrode (O1) reached significant values at 1 hour (57.2+/-8.5%; p < 0.05), 3 hours (59.4+/-7.6%; p < 0.05) and 6 hours (63.4+/-9.8%; p < 0.05) after Cerebrolysin administration. Enhancement in relative alpha power was accompanied by a generalized decrease in slow delta activity that was maximum at 6 hours after Cerebrolysin intake. A significant improvement in memory performance, evaluated with items of the ADAS cog, was also found in elderly people taken a single dose of oral Cerebrolysin (6.9+/-1.0 errors at baseline versus 4.9+/-1.0 errors after treatment; p < 0.01). This memory improvement was more evident in recognition (2.8+/-0.6 errors vs. 1.5+/-0.7 errors; p < 0.05) than in recall tasks (4.1+/-0.5 errors versus 3.4+/-0.5 errors; ns). These data indicate that Cerebrolysin potentiates brain alpha activity, reduces slow EEG delta frequencies and improves memory performance in healthy elderly humans, suggesting that this compound activates cerebral mechanisms related to attention and memory processes. According to the present results, it seems that oral Cerebrolysin might be useful for the treatment of memory impairment and brain damage in eldely subjects with or without neurodegenerative disorders.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 21 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 14%
Student > Ph. D. Student 3 14%
Professor 2 10%
Student > Bachelor 2 10%
Student > Master 2 10%
Other 2 10%
Unknown 7 33%
Readers by discipline Count As %
Medicine and Dentistry 4 19%
Neuroscience 4 19%
Psychology 2 10%
Agricultural and Biological Sciences 2 10%
Computer Science 1 5%
Other 1 5%
Unknown 7 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 August 2022.
All research outputs
#20,453,782
of 23,009,818 outputs
Outputs from Journal of neural transmission Supplementum
#91
of 99 outputs
Outputs of similar age
#106,264
of 108,242 outputs
Outputs of similar age from Journal of neural transmission Supplementum
#8
of 10 outputs
Altmetric has tracked 23,009,818 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 99 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 108,242 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.